% | $
Quotes you view appear here for quick access.

Allergan plc Message Board

skin_man54 4 posts  |  Last Activity: May 13, 2010 7:57 AM Member since: May 12, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by skin_man54 May 12, 2010 5:38 PM
    skin_man54 skin_man54 May 13, 2010 7:57 AM Flag

    BOTOX is more like $1.3 b. Always been fragile. BOTOX is starting to get competition in Eurozone from RELOXIN.

    We thought this was just another Palomar technology until we looked at it closer. The combo makes this a different animal altogether. No wonder JNJ left Palomar last year.

    We didn't know anything about J Plasma. We found you guys from this on Goog. Then we saw your 510K and that got attention.

    Bovie Medical Announces Joint Venture to Manufacture and Market J-Plasma; A New Surgical Plasma Technology Device
    Business Wire, March 2, 2000
    12Next Business Editors, Health/Medical Writers

    MELVILLE, N.Y.--(BUSINESS WIRE)--March 2, 2000

    Bovie Medical Corporation (the "Company" or "Bovie") (OTC Bulletin Board Symbol:BOVI), a manufacturer and marketer of electrosurgical products today announced that it entered into a co-equal joint venture with a European technology development company to manufacture and market worldwide, J-Plasma, a new-patented plasma technology that could significantly improve current surgical procedures. Although J-Plasma will initially be utilized in plastic surgery and dermatology, management anticipates possible uses in many types of surgery, including cancer, neuro, cardiovascular and gynecologic and endoscopic procedures.

    Related Results

    Bovie Medical Corporation Announces Submission of 510(k) Application for Its...
    Acoustic Monitoring of Plasma Arcs in Direct Current Electric Arc Furnaces
    Time-Course of Tissue Factor Plasma Level in Patients with Acute Coronary...
    Plasma Prohepcidin as a Negative Acute Phase Reactant after Large Cardiac...
    Regionally-Selective Cell Colonization of Micropatterned Surfaces Prepared by...
    The device produces a stable thin focused beam of ionized gas that can be controlled in a wide range of temperatures and intensities providing the surgeon with precision, minimal invasiveness and an absence of conductive currents during surgery.

    The joint venture is developing its first commercial prototypes for uses in dermatology and plastic surgery and upon their completion; Bovie intends to file the appropriate applications with the Food and Drug Administration (FDA) for these uses. Applications in other areas of surgery require further testing and will be subject to FDA approvals.

    Bovie's management believes J-Plasma is potentially an important advance to traditional surgical operations and will be cost effective and complementary to Bovie's electrosurgical product line.

  • Reply to


    by skin_man54 May 12, 2010 5:38 PM
    skin_man54 skin_man54 May 12, 2010 9:21 PM Flag

    I just got a glimpse of the LR results. It was packaged for higher pay grades. My product mgr was handed the project.

    No names in the envelope. No return address. It just mentioned JPlasma and that's how I figured it came from here. It jolted more than a few guys.

    The subjects were elderly females I'd guess 60s> Foreheads, eyes. Really good LR comps on crow's feet.

    I was hoping the JNJ boys were focused elsewhere...

  • skin_man54 by skin_man54 May 12, 2010 5:46 PM Flag

    ...No more wrinkles.

    Ablate the epithelium with cool plasma...spray with OMRIX tissue-welding fibrin...wrinkles gone. No stretched look at all.

    PRAY the top AGN boys get the company who has this technology. J Plasma

    Apparently it isn't too late. Rumor has an already acquisition under (BIG players) way but not yet done.

    I saw the pics before they went up top. Drop dead good.

  • skin_man54 by skin_man54 May 12, 2010 5:38 PM Flag

    Helium Plasma & JNJ's EVICIL being examined at the top.

    Came in the window. Plain envelope.

    WOW! What a secret! Who could have figured?

233.61+2.52(+1.09%)2:06 PMEDT